Higher levels of endogenous estradiol are associated with frailty in postmenopausal women from the Toledo study for healthy aging

2.50
Hdl Handle:
http://hdl.handle.net/10547/593449
Title:
Higher levels of endogenous estradiol are associated with frailty in postmenopausal women from the Toledo study for healthy aging
Authors:
Carcaillon, L.; García-García, F. J.; Tresguerres, J. A. F.; Gutiérrez Avila, G.; Kireev, R.; Rodríguez-Mañas, Leocadio
Abstract:
Adverse effects of higher endogenous estradiol (E2) levels on various clinical outcomes and on determinants of the frailty syndrome have recently been reported. However, there are no data about the potential relationship between E2 and frailty. We aimed to study the association between E2 levels and frailty among older postmenopausal women not taking hormonal therapy.
Affiliation:
Hospital Universitario de Getafe, Toledo
Citation:
Carcaillon, L. et al (2012) 'Higher levels of endogenous estradiol are associated with frailty in postmenopausal women from the toledo study for healthy aging' J. Clin. Endocrinol. Metab. 97 (8):2898-906
Publisher:
Endocrine Society
Journal:
The Journal of clinical endocrinology and metabolism
Issue Date:
Aug-2012
URI:
http://hdl.handle.net/10547/593449
DOI:
10.1210/jc.2012-1271
PubMed ID:
22679065
Additional Links:
http://press.endocrine.org/doi/abs/10.1210/jc.2012-1271
Type:
Article
Language:
en
ISSN:
1945-7197
Appears in Collections:
IHR Institute for Health Research

Full metadata record

DC FieldValue Language
dc.contributor.authorCarcaillon, L.en
dc.contributor.authorGarcía-García, F. J.en
dc.contributor.authorTresguerres, J. A. F.en
dc.contributor.authorGutiérrez Avila, G.en
dc.contributor.authorKireev, R.en
dc.contributor.authorRodríguez-Mañas, Leocadioen
dc.date.accessioned2016-01-14T12:17:22Zen
dc.date.available2016-01-14T12:17:22Zen
dc.date.issued2012-08en
dc.identifier.citationCarcaillon, L. et al (2012) 'Higher levels of endogenous estradiol are associated with frailty in postmenopausal women from the toledo study for healthy aging' J. Clin. Endocrinol. Metab. 97 (8):2898-906en
dc.identifier.issn1945-7197en
dc.identifier.pmid22679065en
dc.identifier.doi10.1210/jc.2012-1271en
dc.identifier.urihttp://hdl.handle.net/10547/593449en
dc.description.abstractAdverse effects of higher endogenous estradiol (E2) levels on various clinical outcomes and on determinants of the frailty syndrome have recently been reported. However, there are no data about the potential relationship between E2 and frailty. We aimed to study the association between E2 levels and frailty among older postmenopausal women not taking hormonal therapy.en
dc.language.isoenen
dc.publisherEndocrine Societyen
dc.relation.urlhttp://press.endocrine.org/doi/abs/10.1210/jc.2012-1271en
dc.rightsArchived with thanks to The Journal of clinical endocrinology and metabolismen
dc.subjectendogenous estradiolen
dc.subjectToledo Study for Healthy Agingen
dc.subjectageingen
dc.subjectpostmenopausal womenen
dc.subject.meshAgeden
dc.subject.meshC-Reactive Proteinen
dc.subject.meshCohort Studiesen
dc.subject.meshEstradiolen
dc.subject.meshFemaleen
dc.subject.meshFrail Elderlyen
dc.subject.meshHumansen
dc.subject.meshPostmenopauseen
dc.titleHigher levels of endogenous estradiol are associated with frailty in postmenopausal women from the Toledo study for healthy agingen
dc.typeArticleen
dc.contributor.departmentHospital Universitario de Getafe, Toledoen
dc.identifier.journalThe Journal of clinical endocrinology and metabolismen

Related articles on PubMed

All Items in UOBREP are protected by copyright, with all rights reserved, unless otherwise indicated.